220 results about "Abnormal cells" patented technology

The invention relates to an antibody drug conjugate which is shown in a formula (I) and contains two or more bioactive molecules with different action mechanisms, a preparation method of the antibody drug conjugate, and application of the antibody drug conjugate in prevention and / or treatment of diseases related to abnormal cell activity, including but not limited to prevention and / or treatment of tumor diseases. # imgabs0 #

The present invention relates, in part, to methods, compounds, and compositions of KRAS G12D inhibitors in combination with dual RAF / MEK inhibitors for the treatment of abnormal cell growth (e.g., cancer).

The present invention relates to compounds of formula (I)or pharmaceutically acceptable salts thereof, wherein Ring A, R1-R8, and n are defined herein. The novel benzisoxazole sulfonamide derivatives are useful in the treatment of abnormal cell growth, such as cancer, in patients. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in patients.

The present disclosure relates to compounds of Formula (I′):and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparation these compounds, compositions comprising these compounds, and methods of using them in the prevention or treatment of abnormal cell growth in mammals, especially humans.

The invention belongs to the technical field of medical instruments, and discloses a digestive endoscopy diseased region accurate positioning and marking device which comprises a controller, an endoscope hose is fixedly connected to the bottom of the controller, and an instrument insertion opening is formed in the right side of the controller. Through the arrangement of the sleeve, the dye tube, the pressurization air bag and the baffle, after an operator observes a diseased region through the endoscope hose, the operator only needs to align the endoscope hose to the diseased region, and by pressing the pressurization air bag, air in the pressurization air bag enters the dye tube through the inner hose; the baffle can be pushed to rotate outwards under the action of air pressure, meanwhile, methylene blue in the dye tube is sprayed out under the action of air flow, a diseased region is marked, the methylene blue can be absorbed by normal mucous membrane cells, and diseased tissue shows dyeing difference due to abnormal cell function and poor absorption capacity, so that the diseased region is marked. Therefore, the effect of accurate positioning is achieved.

An antibody-drug conjugate as shown in formula I, a preparation method therefor, and a use thereof in prevention and / or treatment of diseases related to abnormal cell activity, including but not limited to a use in prevention and / or treatment of tumor diseases.

The invention relates to an antibody composition for detecting abnormal CTL (cytotoxic T lymphocyte) cells of hemophagocytic syndrome and application of the antibody composition, and the antibody composition comprises a CD2 antibody, a CD3 antibody, a CD4 antibody, a CD5 antibody, a CD7 antibody, a CD8 antibody, a CD56 antibody, a CD57 antibody, a Granzyme B antibody, a Perforin antibody, a TRBC1 antibody and a CD45 antibody. In the technical scheme provided by the invention, key phenotypic characteristics of CTL (Cytotoxic Lymphocyte) can be completely covered by various antibodies aiming at T cell and NK cell surface markers, T large granular lymphocyte markers, cytotoxic granular proteins, T cell receptor constant regions and leukocyte common antigens; wherein the clonality of the CTL cells is judged through the expression level of the TRBC1 antibody, and the cytotoxic function activity of the CTL cells is evaluated through the expression levels of Granzyme B and Perforin.

Provided are a class of fused ring compounds, and a preparation method therefor and the use thereof. Specifically, provided are a compound of the following formula or a pharmaceutically acceptable form thereof, a pharmaceutical composition thereof, and a preparation method therefor and the use thereof. The compound can be used as a drug for treating diseases related to abnormal cell proliferation.

The invention provides a medical cell detection method. The medical cell detection method comprises the following steps: S1, collecting a cell image for preprocessing; s2, carrying out structured processing and coding processing on the multi-modal data; s3, performing feature extraction on the cell image and the multi-modal data; s4, fusing the cell image and the multi-modal data; s5, inputting the fused feature vector into a segmentation head of the FastSAM; s6, generating a segmentation mask of the image; s7, judging whether the cells are abnormal or not; s8, re-sampling the abnormal cells for cell culture; s9, collecting a cell image in the cell culture equipment in real time, and preprocessing; s10, inputting the cell image into a FastSAM model, and analyzing various indexes of the cell based on the generated segmentation mask; according to the method, cell images, cases, clinical examination results and other multi-modal data are combined, the characteristics of the cells are known more comprehensively, and the detection accuracy is improved.

The invention relates to the technical field of image processing, in particular to a stomach cancer tissue typing auxiliary recognition method based on digital pathological sections. According to the method, morphological feature recognition is carried out on edge information in a grayscale image of a slice, and normal cell edges and abnormal cell edges are screened out according to the size of morphological feature indexes and the morphology of a cell edge curve. A first abnormal area and a second abnormal area are screened out according to the proximity relation, then enhancement coefficients of the two abnormal areas are calculated and enhanced, and a gastric cancer tissue typing recognition result is obtained according to the enhanced stomach pathology image. According to the invention, the object of the enhancement process is only limited to the abnormal region, and different degrees of enhancement are realized for different types of abnormal regions, so that the calculation amount of the enhancement process is reduced, the enhancement process has pertinence, excessive enhancement cannot be caused, and a clear slice image is obtained for tissue typing identification; and the tissue typing recognition efficiency is improved.

Methods are disclosed for treating chronic lymphocytic leukemia (CLL), and other diseases, comprising administrating to a patient an anti-CLECL1 antibody or antigen-binding fragment thereof, as soluble molecules or as components of CAR-T cells or as bi- or tetra-specific antibodies that co-ligate T cells or NK cells and abnormal cells in CLL or other diseases or as bi- or tetra-specific antibodies that bind only the B cells in CLL or only abnormal cells in other diseases. Methods are disclosed for determining residual disease after therapy or predicting disease relapse in a patient comprising analyzing a blood or bone sample from a patient treated for the disease for the presence of CLECL1+ PF cells using a monoclonal antibody to CLECL1 or antigen-binding fragment thereof, wherein reappearance of CLECL1+ PF cells in the blood of the patient is indicative of development of resistance to therapy. Monoclonal antibodies to CLECL1 are disclosed.

The embodiment of the application discloses an abnormality detection method and device for cell entering a shell, electronic equipment and a storage medium. The method comprises the following steps: acquiring detection data in the process that a cell entering shell machine drives the cell to enter a battery shell; generating one or more to-be-detected curves according to the detection data; detecting the one or more to-be-detected curves respectively according to historical detection data to obtain a detection result corresponding to each to-be-detected curve; and determining an abnormality result of the cell entering the shell according to the detection result corresponding to each to-be-detected curve. The embodiment of the application can improve the accuracy of the abnormal cell judgment. The above judgment process does not need manual inspection, improves the intelligent degree of the cell detection process, can effectively determine the main abnormal problems in the production process, and can be solved in a targeted manner, thereby improving the accuracy and efficiency of the abnormal detection of the lithium cell entering the shell process.

A camptothecin compound and a conjugate thereof, or a tautomer thereof, an enantiomer thereof, a diastereomer thereof, or a mixture form thereof, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutical composition thereof, a preparation method therefor, and use thereof. The compound and the conjugate can be used for treating proliferative diseases related to abnormal cell activity.

CD24-positive malignant and benign tumors are treated by administration of a naturally occurring or modified oncolytic Zika virus. Diseases associated with abnormal T cell activation or T cell-mediated autoimmunity, wherein CD24 expression is increased, are also expected to be treated by administration of a naturally occurring or modified oncolytic Zika virus. Also contemplated are compounds and methods for treating and / or preventing Zika virus infection in a subject.

The invention relates to novel cell-binding agent-maytansinoid conjugate having a self-immolative peptide linker and more specifically to conjugates of formula (I). The invention also provides novel maytansinoid compounds of formula (II), (III), (IV) or (V). The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.

A polymeric nanoparticle is disclosed which comprises:(i) at least one disease-associated antigen which is capable of producing a T-cell response, wherein the disease-associated antigen is encapsulated in the nanoparticle;(ii) at least one adjuvant; and(iii) a dendritic cell targeting moiety which is attached to the outer surface of the nanoparticle.Use of the nanoparticle for treating diseases associated with abnormal cell growth or an infection is also disclosed.

The invention discloses a direct counting method and device for detecting the number of fluorescence-labeled rare abnormal cells in a blood sample. Aiming at the problem that direct counting of low-abundance cells is difficult to realize in a conventional blood container by a traditional detection means, the method realizes rapid and direct counting of rare abnormal cells by performing narrow-band filtering, efficient collection and high signal-to-noise ratio detection on a fluorescence signal emitted by a static blood sample. The device comprises a lighting source module, an exciting light and emitted light narrow-band filtering module, a light beam collimation and beam expansion module, a sample bearing module, an emitted light collection and detection module and a data processing and counting module. Accurate counting of the extremely-low-abundance fluorescence labeling abnormal cells can be completed in a conventional transparent container without flow sorting or complex treatment of a blood sample, and the method has the advantages of being easy and convenient to operate, high in detection speed, suitable for clinical screening and the like.

The invention relates to novel cell-binding agent-maytansinoid conjugate having a self-immolative peptide linker and more specifically to conjugates of formula (I). The invention also provides novel maytansinoid compounds of formula (II), (III), (IV) or (V). The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.

The invention discloses an antibody composition for detecting mother cell plasma cell-like dendritic cells. The antibody composition comprises a first group of antibodies, a second group of antibodies, a third group of antibodies and a fourth group of antibodies, the first group of antibodies comprises a CD36 antibody, a CD4 antibody, a CD14 antibody, a CD56 antibody, a CD5 antibody, a CD3 antibody, a CD8 antibody, a CD2 antibody, a CD7 antibody and a CD45 antibody; the second group of antibodies comprises an HLA-DR (Human Leukocyte Antigen-DR) antibody, a CD33 antibody, a CD34 antibody, a CD56 antibody, a CD117 antibody, a CD123 antibody, a CD19 antibody, a CD38 antibody and a CD45 antibody; the third group of antibodies comprises a CD303 antibody, a CD304 antibody, a CD41 antibody, a CD56 antibody, a CD13 antibody, a CD85j antibody, a CD64 antibody, a CD15 antibody and a CD45 antibody; and the fourth group of antibodies comprises TdT, MPO, CD56, cCD3, CD10, cCD22 and CD45 antibodies. The antibody composition can be used for accurately detecting tumor abnormal BPDCN cells.

The present disclosure relates to novel compounds that act as modulators of cereblon (CRBN). The compounds promote CRBN-mediated ubiquitination and proteasomal degradation of oncogenic proteins such as GSPT1 and MYC, thereby suppressing abnormal cell growth. Pharmaceutical compositions containing the compounds and methods of using the compositions for the treatment of cancers, particularly solid tumors, are also provided.

The present disclosure relates to compounds of Formula (I′):and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparation these compounds, compositions comprising these compounds, and methods of using them in the prevention or treatment of abnormal cell growth in mammals, especially humans.

The invention provides a genetic engineering strain and a construction method thereof, the strain is a target gene deleted strain obtained by knocking out a target gene in a rod-shaped bacterial strain, and the target gene is one of minC and minD genes or a gene combination thereof. According to the present invention, the minC and / or minD gene deletion strain is obtained by knocking out the minC and / or minD gene in the rod-shaped bacterial strain, such that cell division abnormality can be caused, chromosome-free small cells are generated, and the small cells have characteristics of biological activity, no chromosome DNA, and no growth or division propagation. The small cells can generate smaller body immune response, and meanwhile, the LPS modified by the small cells can generate smaller cytotoxic reaction, so that side effects can be greatly reduced when the small cells are applied to human or animal bodies.

Disclosed herein is a method for training a network to detect and classify abnormal pathologies in images if cells. Specifically, the network uses a deep framework optimally trained to detect and classify abnormal cervical cells in pap smear images.

The invention provides a cervical cell identification method and system. The method comprises the following steps: identifying a qualified visual field area in a pathological image to be detected; extracting contour coordinate information of each to-be-detected cervical cell in the qualified view area, and segmenting and extracting a feature vector of each to-be-detected cervical cell; and querying in a query set based on the feature vector of each to-be-detected cervical cell to obtain the category of each to-be-detected cervical cell. According to the method, the image quality of each view area in the pathological image to be detected is analyzed, so that the output reliability of the final recognition result is ensured, and prediction deviation and errors caused by low-quality data are avoided; each cervical cell in the qualified visual field area is identified, so that main targets to be detected are not missed, and the workload of labeling is reduced by learning the common morphological characteristics of the bottom layers of various cervical cells; through a query classification mode, the satisfactory identification accuracy can be achieved only through fewer abnormal cell annotations compared with a traditional method.

The invention discloses a method and a device for judging network access perception degradation, electronic equipment and a storage medium. The method comprises the steps that a first object of a target line is determined, the target line comprises a plurality of first cells, and the first cells are the network coverage range of a communication base station of each high-speed rail station on the target line; determining a third index based on the association degree of the first index and the second index; the first index is a key quality index of each first cell network, and the second index is an index of a network operation state and network technical performance of each first cell; the third index is a first index strongly related to the internet surfing perception of the first object; determining a first index threshold value of the third index, and determining a second object based on the third index and the first index threshold value; the second object is an object with degraded internet access perception in the first object; and determining the distribution condition of the second object in each first cell, and determining an abnormal cell according to the distribution condition. According to the method, the wireless network sensing condition of the high-speed rail line can be accurately judged.

The present application provides a linker, an antibody-drug conjugate, a preparation method therefor and the use thereof in the prevention and / or treatment of diseases related to abnormal cell activity, including but not limited to the prevention and / or treatment of tumor diseases.

The present invention relates to the field of medical therapy of lesions detrimental to a body. The system is capable of treatment with a non-invasive, ionizing kV energy radiation source. Locally focused energy can be used to definitively treat, or as an adjuvant to enhance immune modulators, to eliminate tumors. Distributed external beam entry points produce a significant advantageous dose profile at depth as intersecting beams accumulate in a narrow focus to treat a selected volume. Targeted disease may have enhanced sensitivity to the radiation by taking up an ionizing-radiation, treatment-localizing agent. This increases the effectiveness of an energy dose in the lesion. The pattern of beam output is effectively directed towards a desired location and kV x-rays traveling towards undesired locations, such as healthy tissue, are quenched. Targeting a lesion within the body with volumetrically discrete energy dose deposition can beneficially impact harmful lesions. Aiming the beam at a pathologic target is done while moving an x-ray source mechanically around a patient to distribute surface dose. The purpose of the focused energy deposition is to destroy and disable pathologic physiology, such as malignant masses. More specifically this invention relates to a system, which optimizes delivery of ionizing kV beams to a lesion alone or one containing treatment-localizing agents in higher concentration than the surrounding normal tissues. Thereby an optimal delivery of ionizing radiation becomes more destructive to a mass of abnormal cells upon interaction with the targeted site.

A pyrrolopyrimidine or pyrrolopyridine derivative and its medical use. Specifically, the compound has the structure shown in formula I, has good inhibitory effect on focal adhesion kinase (FAK), and can inhibit its related signal pathways, and can be prepared for treating or preventing diseases related to cancer, pulmonary arterial hypertension, pathological angiogenesis, etc., and can be particularly used for treating diseases caused by excessive or abnormal cell proliferation, such as tumors or cancers.

The present disclosure relates to a Camptothecin compound having anti-tumor activity, a preparation method therefor, and an application thereof. Specifically, the present disclosure relates to a compound as shown below or a pharmaceutically acceptable form thereof, a pharmaceutical composition thereof, a preparation method therefor, and a use thereof. The compound can be used as a drug for treating diseases in abnormal cell proliferation,

The embodiments of the present disclosure provide a method, device, electronic device, storage medium and program product for detecting abnormal cells, which relate to the field of battery technology. The method comprises: determining a cell to be detected; obtaining a plurality of measurement parameters corresponding to a plurality of sequential processes in the cell detection process for the cell to be detected; for each first process, determining the prediction parameters of the first process based on the measurement parameters of the previous process of the first process and the state transition information corresponding to the first process; and determining the abnormal detection results of the cell to be detected based on the differences between the measurement parameters and the prediction parameters corresponding to each first process. The embodiments of the present disclosure effectively detect abnormal cells without puncturing the diaphragm, reduce the missed detection rate of abnormal cell detection, thereby effectively eliminating abnormal cells caused by metal foreign matter and diaphragm defects, and improve the quality and safety of the produced batteries.